Free Newsletter
Breakthrough points to new cancer drug class
Researchers are hailing new work decoding a key enzyme as a breakthrough that could lead to an entirely new class of anti-cancer therapies. Emmanuel Skordalakes, a professor at the Wistar Institute in Philadelphia, says that telomerase is present in nearly all cancers and presents an ideal target for drug researchers. Once telomerase is activated in cancer cells, it opens the door to endless replication. Inhibiting that process could have enormous implications.
"That means that a drug that deactivates telomerase would likely work against all cancers, with few side effects," says the scientist. His team was able to create a three-dimensional structure of the active region of the enzyme by using X-ray crystallography.
Obviously much work remains on whether a telomerase inhibitor can effectively work as billed. But researchers in the field say that the new work represents a major breakthrough in cancer biology.
- check out the AFP report
Related Article:
Two pioneers first women to get top research prize
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact




